A new publication concerning zenagamtide was released on August 15, 2026. The paper, titled "Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial," appeared in The Lancet.
The publication describes a phase 2, dose-finding trial evaluating zenagamtide, described as a unimolecular GLP-1 and amylin receptor agonist, in people with type 2 diabetes. The study design is reported as multicentre, randomised, parallel-group, double-blind, and placebo-controlled.
This entry reflects only that the trial results have been published in a peer-reviewed journal, as indicated by the listing. No specific efficacy or safety outcomes from the trial are included in this brief, since that data was not provided.
Zenagamtide is noted here in connection with albiglutide, another GLP-1 receptor agonist compound, within the context of unapproved research status. Readers should note that the compound's regulatory status is unapproved and for research purposes only, based on the information provided.
For more background on this compound class and related research, readers can consult the compound overview page.